BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...BenevolentAI $115.0 ReNeuron Group plc (LSE:RENE) $107.1 4D pharma plc (LSE:DDDD) $98.2 Inivata Ltd. $97.4 Carrick Therapeutics Ltd....
BioCentury | Feb 1, 2020
Distillery Therapeutics

CDK7 inhibition for treating small cell lung cancer

...further improved survival compared with any of the treatments alone or chemotherapy plus the mAb. Carrick Therapeutics Ltd....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...BenevolentAI $115.0 ReNeuron Group plc (LSE:RENE) $107.1 4D pharma plc (LSE:DDDD) $98.2 Inivata Ltd. $97.4 Carrick Therapeutics Ltd....
BioCentury | Oct 17, 2019
Clinical News

Syros prioritizing oral CDK7, dropping IV after Phase I data

...breast cancer. At least one other oral CDK7 inhibitor has reached the clinic. CT7001 from Carrick Therapeutics Ltd....
...a Phase I/II trial, as monotherapy and in combination with fulvestrant, to treat solid malignancies. Carrick...
BioCentury | Aug 8, 2019
Distillery Therapeutics

CDK7 inhibition for drug-resistant cancers

...in a mouse model of SMO inhibitor-resistant hedgehog-driven medulloblastoma; the inhibitor also extended mouse survival. Carrick...
BioCentury | Jun 29, 2019
Company News

Management tracks: Carrick names Pearson CEO in U.S. push; plus AC Immune, Paratek and more

...Cancer company Carrick Therapeutics Ltd. (Dublin, Ireland) hired Tim Pearson as CEO. He succeeds Elaine Sullivan, one of...
...Inc. until its takeout by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), will be based in Boston, where Carrick...
...operations. The company, which also has operations in the U.K, will remain headquartered in Dublin. Carrick...
BioCentury | Nov 21, 2018
Company News

Management tracks: BerGenBio, Alzamend

...1990-98. He is SVP of oncology of Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) and CMO of Carrick Therapeutics Ltd....
BioCentury | Oct 11, 2018
Company News

Management tracks: Former Baxalta exec joins VisionGate; Carrick names Golumbeski chair

...customer operations at Baxalta Inc., which Shire plc (LSE:SHP; NASDAQ:SHPG) acquired in 2016. Cancer company Carrick Therapeutics Ltd....
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...Bill & Melinda Gates Foundation , Malin, CF Woodford Equity Income Fund, Woodford Investment Management Carrick Therapeutics Ltd....
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...Behind CRISPR Therapeutics’ and Kymab’s rounds were a $95 million series A for Irish newco Carrick Therapeutics Ltd....
...Five of the other funds invested in 17 new companies between them, including heavy hitters Carrick...
...2016 Cambridge, U.K. University of Cambridge £12M ($16.1M) Small molecules targeting RNA-modifying enzymes Cancer Preclinical Carrick Therapeutics Ltd....
Items per page:
1 - 10 of 13
BioCentury | Feb 10, 2020
Finance

Woodford pain continues as report suggests deal to sell private biotech stakes falls through

...BenevolentAI $115.0 ReNeuron Group plc (LSE:RENE) $107.1 4D pharma plc (LSE:DDDD) $98.2 Inivata Ltd. $97.4 Carrick Therapeutics Ltd....
BioCentury | Feb 1, 2020
Distillery Therapeutics

CDK7 inhibition for treating small cell lung cancer

...further improved survival compared with any of the treatments alone or chemotherapy plus the mAb. Carrick Therapeutics Ltd....
BioCentury | Oct 19, 2019
Finance

Woodford’s empire crumbles. U.K biotech stays standing

...BenevolentAI $115.0 ReNeuron Group plc (LSE:RENE) $107.1 4D pharma plc (LSE:DDDD) $98.2 Inivata Ltd. $97.4 Carrick Therapeutics Ltd....
BioCentury | Oct 17, 2019
Clinical News

Syros prioritizing oral CDK7, dropping IV after Phase I data

...breast cancer. At least one other oral CDK7 inhibitor has reached the clinic. CT7001 from Carrick Therapeutics Ltd....
...a Phase I/II trial, as monotherapy and in combination with fulvestrant, to treat solid malignancies. Carrick...
BioCentury | Aug 8, 2019
Distillery Therapeutics

CDK7 inhibition for drug-resistant cancers

...in a mouse model of SMO inhibitor-resistant hedgehog-driven medulloblastoma; the inhibitor also extended mouse survival. Carrick...
BioCentury | Jun 29, 2019
Company News

Management tracks: Carrick names Pearson CEO in U.S. push; plus AC Immune, Paratek and more

...Cancer company Carrick Therapeutics Ltd. (Dublin, Ireland) hired Tim Pearson as CEO. He succeeds Elaine Sullivan, one of...
...Inc. until its takeout by GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), will be based in Boston, where Carrick...
...operations. The company, which also has operations in the U.K, will remain headquartered in Dublin. Carrick...
BioCentury | Nov 21, 2018
Company News

Management tracks: BerGenBio, Alzamend

...1990-98. He is SVP of oncology of Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) and CMO of Carrick Therapeutics Ltd....
BioCentury | Oct 11, 2018
Company News

Management tracks: Former Baxalta exec joins VisionGate; Carrick names Golumbeski chair

...customer operations at Baxalta Inc., which Shire plc (LSE:SHP; NASDAQ:SHPG) acquired in 2016. Cancer company Carrick Therapeutics Ltd....
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...Bill & Melinda Gates Foundation , Malin, CF Woodford Equity Income Fund, Woodford Investment Management Carrick Therapeutics Ltd....
BioCentury | May 25, 2017
Finance

Europe’s translational springtime

...Behind CRISPR Therapeutics’ and Kymab’s rounds were a $95 million series A for Irish newco Carrick Therapeutics Ltd....
...Five of the other funds invested in 17 new companies between them, including heavy hitters Carrick...
...2016 Cambridge, U.K. University of Cambridge £12M ($16.1M) Small molecules targeting RNA-modifying enzymes Cancer Preclinical Carrick Therapeutics Ltd....
Items per page:
1 - 10 of 13